title: Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia.
abstract: The Dutch Working Party on Antibiotic Policy (SWAB) develops evidence-based guidelines, aimed at optimalisation of antibiotic use and limitation of the spread of antimicrobial resistance. A revision of the SWAB guideline for the treatment of community-acquired pneumonia (CAP), published in 1998, was considered necessary because of changes in resistance patterns and new insights into the epidemiology, diagnostics and treatment of CAP. In contrast to the former version, this guideline is transmural and has been drawn up according to the recommendations for evidence-based guideline development by a multidisciplinary committee consisting of experts from all relevant professional societies. The 'severity of disease' exhibited by the patient with pneumonia on admission is considered important for the choice of the optimum empirical treatment strategy. Severely ill patients are treated empirically with a drug directed against multiple potential pathogens, including Legionella spp. Classification according to 'severity of disease' can be accomplished with a validated scoring system (Pneumonia Severity Index or CURB-65 score) or pragmatically, based on the site of treatment: an outpatient setting, a clinical ward or an intensive care unit. The Legionella urine antigen test plays an important role in decisions on the choice of initial antibiotic treatment.
authors.affiliation: Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
authors.forename: J A
authors.initials: JA
authors.lastname: Schouten
authors.forename: J M
authors.initials: JM
authors.lastname: Prins
authors.forename: M J
authors.initials: MJ
authors.lastname: Bonten
authors.forename: J
authors.initials: J
authors.lastname: Degener
authors.forename: R E
authors.initials: RE
authors.lastname: Janknegt
authors.forename: J M R
authors.initials: JM
authors.lastname: Hollander
authors.forename: R E
authors.initials: RE
authors.lastname: Jonkers
authors.forename: W J
authors.initials: WJ
authors.lastname: Wijnands
authors.forename: T J
authors.initials: TJ
authors.lastname: Verheij
authors.forename: A P E
authors.initials: AP
authors.lastname: Sachs
authors.forename: B J
authors.initials: BJ
authors.lastname: Kullberg
mesh_terms: D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D004351:Drug Resistance; D006760:Hospitalization; D006801:Humans; D009426:Netherlands; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D012307:Risk Factors; D012985:Software Design
chemical_list: D000900:Anti-Bacterial Agents